Lallemand Biofuels & Distilled Spirits (LBDS) has launched DistilaEdge TC, a bioengineered (Saccharomyces cerevisiae) yeast strain created especially for the production of distilled spirits, marking a significant milestone for the distilled spirits sector.
This groundbreaking strain is engineered to produce significantly higher levels of esters and aromatic compounds, unlocking new creative potential for distillers. Whether you’re crafting high-ester rum or exploring fruit-forward whiskey expressions, DistilaEdge TC delivers exceptional results – all without requiring any changes to your existing workflow. LBDS created this strain in collaboration with Mascoma (a company of Lallemand) who is a leader in research and development of new industrial biotechnology products; their expertise in yeast improvement is highly recognised, most predominantly in the bioethanol field.
“This is a major milestone not just for Lallemand, but for the entire spirits industry,” said Justin van Rooyen, president & general manager of Lallemand Biofuels & Distilled Spirits. “DistilaEdge TC empowers distillers to push the boundaries of flavour and innovation like never before.”
Field trials have shown orders of magnitude increases in ester production, with no impact on fermentation kinetics, yeast health, or yield – a true game-changer for producers seeking complexity and consistency.
The launch of DistilaEdge TC marks the beginning of an ever-expanding DistilaEdge portfolio, focused on delivering cutting-edge microbial innovations to the spirits industry, helping to transform fermentation and elevate spirits. Future additions will include more cutting-edge strains and advanced biotech solutions designed to help distillers explore new territories and fermentation possibilities.
DistilaEdge TC is now available in the United States and distributed through Scott Labs.
